famotidine has been researched along with Cancer of Gastrointestinal Tract in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YD | 1 |
| Wang, J | 1 |
| Shibli, F | 1 |
| Poels, KE | 1 |
| Ganocy, SJ | 1 |
| Fass, R | 1 |
1 other study available for famotidine and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
Topics: Animals; Famotidine; Gastroesophageal Reflux; Gastrointestinal Neoplasms; Humans; Omeprazole; Raniti | 2021 |